An AACR Special Conference on

Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications

October 12-15, 2011
The Fairmont San Francisco
San Francisco, CA

Wednesday, October 12

7:00 p.m.–8:00 p.m.  Opening Keynote Address
Chairperson: Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX
Modeling breast cancer in three dimensions: Lessons learned
Joan S. Brugge, Harvard Medical School, Boston, MA

8:00 p.m.–9:30 p.m.  Networking Reception

Thursday, October 13

7:30 a.m.–8:30 a.m.  Continental Breakfast

8:30 a.m.–10:30 a.m.  Session 1
Genomics/Epigenomics
Chairperson: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA
Parity-associated changes in the human breast and their relevance to breast cancer
Kornelia Polyak

Integrated molecular profiles of primary breast tumors: Improved prognostic power
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Institute for Cancer Research, Oslo, Norway

Breast cancer epigenetics: From DNA methylation to noncoding RNAs
Manel Esteller, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

Systems epigenomics for prognosis and personalized treatment
Tim Hui-Ming Huang, University of Texas Health Science Center in San Antonio, San Antonio, TX
10:30 a.m.-11:00 a.m. Break

11:00 a.m.-12:30 p.m. Session 2
Metabolomics
Chairperson: Lewis C. Cantley, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

PI 3-kinase and cancer cell metabolism
Lewis C. Cantley

Nutrient addiction in the breast: Strong subtype-specific activities and potential therapeutic opportunities
Luika Timmerman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Mechanisms involved in reduction in risk of breast cancer by metformin and similar compounds
Michael Pollak, McGill University, Montreal, QC, Canada

12:30 p.m.-2:30 p.m. Lunch on own

2:30 p.m.-4:30 p.m. Session 3
Targeted Therapies (HER2, PIK3CA, Basal-like)
Chairperson: José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA

Title to be announced
José Baselga

Targeting IGF signaling in breast cancer subtypes
Douglas Yee, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

Targeting HER2: Current and future approaches
Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA

Basal-like breast cancer: What is the target?
Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

4:30 p.m.-7:00 p.m. Dinner on own

7:00 p.m.-10:00 p.m. Poster Session A/Reception
Friday, October 14

7:30 a.m.-8:30 a.m.  Continental Breakfast

8:30 a.m.-10:30 a.m.  Session 4
Inflammation and Cancer as Systemic Disease
Chairperson: Patricia S. Steeg, National Cancer Institute, Bethesda, MD

The breast tumor microenvironment, tumor heterogeneity, and clinical outcome
Morag Park, Canadian Institutes of Health Research, Montréal, QC, Canada

Lymphocytes and the control of breast cancer metastasis
Michael Karin, University of California San Diego, La Jolla, CA

Tumor-entrained neutrophils inhibit seeding in the premetastatic lung
Robert Benezra, Memorial Sloan-Kettering Cancer Center, New York, NY

A LPA1 antagonist, Debio 0719, inhibits breast cancer metastasis and induces dormancy
Patricia S. Steeg

10:30 a.m.-11:00 a.m.  Break

11:00 a.m.-12:30 p.m.  Session 5
Noncoding RNAs
Chairperson: Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX

Long noncoding RNAs in breast cancer progression
Howard Y. Chang, Stanford University, Stanford, CA

The role of noncoding RNA regulators of self renewal in cancer
Michael F. Clarke, Stanford University School of Medicine, Palo Alto, CA

The dodecalogus of noncoding RNAs involvement in breast cancer: 2011 version
George A. Calin, University of Texas MD Anderson Cancer Center, Houston, TX

12:30 p.m.-3:30 p.m.  Poster Session B/Lunch
3:30 p.m.-5:00 p.m.  Session 6
Stem Cells
Chairperson: Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX

EMT programs and therapeutic resistance of breast cancer stem cells
Jeffrey M. Rosen

Phenotypic and functional characterization of the mammary luminal epithelial cell hierarchy
John P. Stingl, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Mammary stem cell niche and implications for breast cancer
Rama Khokha, University of Toronto Ontario Cancer Institute, Toronto, ON, Canada

5:00 p.m.-6:00 p.m.  Panel Discussion
Transforming Translational Research: Innovation through Collaboration Between Women and Scientists
Presented by The Love/Avon Army of Women

Panelists:
Susan M. Love, Dr. Susan Love Research Foundation, Santa Monica, CA
Jennifer L. Ivanovich, Washington University School of Medicine, St. Louis, MO
Thea D. Tlsty, University of California School of Medicine, San Francisco, CA
Leslie Bernstein, City of Hope, Duarte, CA

6:00 p.m.    Evening off / Dinner on own
Saturday, October 15

7:30 a.m.-8:30 a.m.  Continental Breakfast

8:30 a.m.-9:30 a.m.  Keynote Address
Chairperson: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA
Title to be announced
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

9:30 a.m.-10:00 a.m.  Break

10:00 a.m.-11:30 a.m.  Session 7
Endocrine Resistance
Chairperson: José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA

Epigenetic and cistromic determinants of endocrine dependence
Myles Brown, Dana-Farber Cancer Institute, Boston, MA

Endocrine resistance: Insights from next-gen sequencing
Matthew J. Ellis, Washington University Siteman Cancer Center, St. Louis, MO

Escape pathways contributing to endocrine resistance in breast cancer
C. Kent Osborne, Baylor College of Medicine Cancer Center, Houston, TX

11:30 a.m.  Departure